| __timestamp | Axsome Therapeutics, Inc. | Grifols, S.A. |
|---|---|---|
| Wednesday, January 1, 2014 | 1392830 | 660772000 |
| Thursday, January 1, 2015 | 2419289 | 736435000 |
| Friday, January 1, 2016 | 6343648 | 775266000 |
| Sunday, January 1, 2017 | 7206691 | 860348000 |
| Monday, January 1, 2018 | 9351522 | 814775000 |
| Tuesday, January 1, 2019 | 13598030 | 942821000 |
| Wednesday, January 1, 2020 | 28896749 | 985616000 |
| Friday, January 1, 2021 | 66646205 | 1061508000 |
| Saturday, January 1, 2022 | 159253661 | 1190423000 |
| Sunday, January 1, 2023 | 323123000 | 1254234000 |
| Monday, January 1, 2024 | 411359000 |
Unleashing the power of data
In the world of pharmaceuticals, operational efficiency is key. This analysis compares the Selling, General, and Administrative (SG&A) expenses of Grifols, S.A. and Axsome Therapeutics, Inc. from 2014 to 2023. Grifols, a seasoned player, consistently reported higher SG&A expenses, peaking at approximately 1.25 billion in 2023. This reflects a steady growth of around 90% over the decade. In contrast, Axsome Therapeutics, a rising star, saw its SG&A expenses skyrocket by over 23,000%, from a modest 1.4 million in 2014 to 323 million in 2023. This dramatic increase underscores Axsome's aggressive expansion strategy. While Grifols maintains a stable trajectory, Axsome's rapid growth highlights its dynamic approach in the competitive pharmaceutical landscape. This comparison offers a fascinating glimpse into how established and emerging companies allocate resources to drive growth and innovation.
AstraZeneca PLC and Grifols, S.A.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Bio-Techne Corporation and Grifols, S.A.
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and Axsome Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Opthea Limited
Who Optimizes SG&A Costs Better? Grifols, S.A. or Novavax, Inc.
Breaking Down SG&A Expenses: Grifols, S.A. vs Amphastar Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Axsome Therapeutics, Inc. vs ADMA Biologics, Inc.
Axsome Therapeutics, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Axsome Therapeutics, Inc. and Mesoblast Limited
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Axsome Therapeutics, Inc. or Xencor, Inc.: Who Manages SG&A Costs Better?